GlassScriptPhysician profile
Dina Malak Mourice
NPI 1619336096
$3,798.15
in general payments reported to CMS, 2019-2025
20 companies · $35.25 in 2025
The $35.25 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $680 · 2022: $1,309 · 2023: $784 · 2024: $990 · 2025: $35.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $845.83 | 2022-2025 | |
| Novo Nordisk INC | $827.75 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $318.66 | 2022-2024 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $310.40 | 2021-2023 | Shingrix |
| Janssen Pharmaceuticals, INC | $262.80 | 2022 | |
| Amgen INC. | $212.65 | 2021-2024 | Evenity, Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $181.91 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $161.63 | 2022-2023 | |
| Pfizer INC. | $137.87 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.74 | 2023 | Jardiance |
| Mannkind Corporation | $122.74 | 2021 | |
| Lilly USA, LLC | $109.13 | 2022-2024 | Jardiance, Zepbound, Emgality |
| Sanofi-Aventis U.S. LLC | $40.50 | 2022 | |
| Exact Sciences Corporation | $35.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $29.13 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.28 | 2024 | Veozah |
| Antares Pharma, INC. | $17.23 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.82 | 2023 | Livalo |
| Dynavax Technologies Corporation | $13.14 | 2024 | Heplisav-B |
| Ironshore Pharmaceuticals INC. | $13.05 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Mourice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.